Renin–angiotensin system (RAS) blocking agents, specifically angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are established therapies to slow progression of chronic kidney disease (CKD) once renal impairment or albuminuria is present. Whether RAS blockade prevents the initial development of CKD among patients with type 2 diabetes and newly diagnosed hypertension who have preserved kidney function and normoalbuminuria is less clear. Prior randomized trials and observational studies produced inconsistent results. This multicenter retrospective cohort study was conducted to address whether initiating ACEI/ARB therapy at the time of antihypertensive treatment start is associated with reduced incidence of new-onset CKD in this population.
Investigators screened a multicenter database comprising 316,693 individuals with type 2 diabetes and newly diagnosed hypertension across seven hospitals in Taiwan. From that population they identified patients who had preserved renal function and normoalbuminuria at the time antihypertensive therapy was begun. After applying a generalized boosted model weighting approach to balance baseline covariates between groups, the analytic cohorts included 3,316 ACEI/ARB users and 1,409 nonusers. The study is described as a multicenter retrospective cohort; further protocol details such as exact inclusion/exclusion criteria, baseline covariates used for weighting, and median follow-up time were not fully reported in the abstract.
Three renal endpoints were prespecified and followed longitudinally:
These outcomes capture both early glomerular injury signaled by albuminuria and established renal function decline measured by eGFR.
Primary associations between RAS blocker exposure and each renal endpoint were estimated using Cox proportional hazards regression. To address potential competing events and the timing of drug exposure, investigators performed confirmatory analyses using competing-risk models and time-dependent exposure Cox models. Baseline characteristics were equalized between ACEI/ARB users and nonusers using a generalized boosted model weighting technique prior to outcome comparisons.
ACEI/ARB therapy was associated with a significantly lower risk of new-onset CKD in this cohort. Key reported effect estimates include:
The association was most robust for prevention of incident albuminuria, and the composite endpoint (albuminuria or reduced eGFR) also showed benefit. These results suggest that initiating an ACEI or ARB when starting blood-pressure therapy in patients with type 2 diabetes and preserved kidney function may confer early kidney protection.
People with type 2 diabetes commonly develop hypertension; together, these conditions increase the risk of kidney damage over time. RAS blockers (ACEIs and ARBs) are commonly used to slow progression once kidney disease is present, but whether they prevent kidney disease when started earlier was uncertain. In this multicenter retrospective study of patients who had preserved kidney function and no protein in the urine at antihypertensive initiation, those who received an ACEI or ARB were about 28% less likely to develop new CKD than those who started other blood-pressure medicines. The clearest benefit was in preventing protein appearing in the urine, an early sign of kidney injury. The authors note that a randomized trial is needed to confirm causality.
Strengths reported or implied by the source include the large initial screening population (over 300,000 patients), multicenter data collection, use of weighting to balance baseline characteristics, and confirmatory analyses incorporating competing-risk and time-dependent exposure models. Limitations inherent to the study design include its retrospective observational nature, potential residual confounding despite weighting, and the absence of randomized assignment. Specifics such as length of follow-up, adherence measures, exact covariates included in the generalized boosted model, and adverse event reporting were not detailed in the abstract and plain language summary and therefore are not reported here.
In this multicenter retrospective cohort, initiation of ACEI or ARB therapy at the start of antihypertensive treatment in patients with type 2 diabetes and preserved kidney function was associated with a lower risk of developing new-onset CKD—particularly incident albuminuria. The findings support the hypothesis that RAS blockade may provide kidney protection even before overt renal impairment, but randomized trials are needed to confirm these observational associations and to inform practice guidelines definitively.